Spondyloarthropathies: References

2. Zeidler H, Mau W, Khan MA. Undifferentiated spondyloarthropathies. Rheum Dis Clin North Am 1992; 18:187-202.

3. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41:58-67.

4. de Keyser F, Elewaut D, de Vos M, et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 1998; 24:785-813.

5. Zeidler H. Undifferentiated arthritis and spondyloarthropathy as a major problem of diagnosis and classification. Scand J Rheumatol 1987; 65(suppl):54-62.

6. Rezaian MM, Aquino ML, Brent LH. Undifferentiated spondyloarthropathy: comparison of clinical manifestations and outcome on HLA-B27 negative and positive patients. Ann Rheum Dis 2000; 59(suppl 1):199.

7. Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002; 31:264-270.

8. Gladman DD, Farewell VT, Kopciuk KA, Cook RJ. HLA markers and progression in psoriatic arthritis. J Rheumatol 1998; 25:730-733.

9. Marsal S, Armadans-Gil L, Martinez M, Gallardo D, Ribera A, Lience E. Clinical, radiographic and HLA association as markers for different patterns of psoriatic arthritis. Rheumatology 1999; 38:332-337.

10. Dougados M, van der Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218-1227.

11. Boyer SG, Lanier PA, Templin WD, Bulkow L. Spondyloarthropathy and rheumatoid arthritis in Alaskan Yupik Eskimos. J Rheumatol 1990; 17:489-496.

12. Sieper J, Braun J. Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum 1995; 38:1547-1554.

13. Cuchacovich R, Japa S, Huang WQ, et al. Detection of bacterial DNA in Latin American patients with reactive arthritis by polymerase chain reaction and sequencing analysis. J Rheumatol 2002; 29:1426-1429.

14. Hammer RE, Maika SD, Richardson JA. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta2 microglobulin: an animal model of HLA-B27-associated human disorders. Cell 1990; 63:1099-1112.

15. Taurog JD, Richardson JA, Croft JT. The germ-free state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180:2359-2364.

16. Amor B. Reiter's syndrome. Rheum Dis Clin North Am 1998; 24:677-695.

17. Collantes-Estevez E, Cisnal del Mazo A, Muñoz-Gomariz E. Assessment of 2 systems of spondyloarthropathy diagnostic and classification criteria (Amor and ESSG) by a Spanish multicenter study. J Rheumatol 1995; 22:246-251.

18. Calin A. Seronegative spondyloarthritides. Med Clin North Am 1986; 70:323-336.

19. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 1984; 27:361-368.

20. van der Linden S, van der Heijde D. Ankylosing spondylitis. In: Ruddy S, Harris J, Sledge CM, editors. Kelley's Textbook of Rheumatology. Philadelphia: WB Saunders, 2001:1039-1053.

21. Khan MA, Khan MK. Diagnostic value of HLA-B27 testing ankylosing spondylitis and Reiter's syndrome. Ann Intern Med 1982; 96:70-76.

22. Reiter H. Über eine bisher unerkannte Spirochateninfektion (Spirochaetosis arthritica). Dtsch Med Wochenschr 1916; 42:1535.

23. Wilkens RF, Arnett FC, Bitter T, et al. Reiter's syndrome. Evaluation of preliminary criteria for definitive disease. Arthritis Rheum 1981; 24:844-849.

24. Deer T, Rosencrance JG, Chillag SA. Cardiac conduction manifestations of Reiter's syndrome. South Med J 1991; 84:799-800.

25. Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris J, Sledge CM, editors. Kelly's Textbook of Rheumatology. Philadelphia: WB Saunders, 2001:1071-1079.

26. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis: a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991; 30:245-250.

27. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994; 33:834-839.

28. Orchard TR, Wordsworth P, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998; 42:387-391.

29. Wollheim FA. Enteropathic arthritis. In: Ruddy S, Harris J, Sledge CM, editors. Kelly's Textbook of Rheumatology. Philadelphia: WB Saunders, 2001:1081-1088.

30. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I. Inflammatory bowel disease and spondyloarthropathy. Arthritis Rheum 2001; 44:2728-2736.

31. Rezaian MM, Brent LH. Undifferentiated spondyloarthropathy: seven-year follow-up study of 357 patients. Arthritis Rheum 2001; 44(suppl):S93.

32. Dougados M, Maetzel A, Mijiyawa M, Amor B. Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis 1992; 51:955-958.

33. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatement of axial and peripheral articular manifestations of the seronegative spondyloarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 1999; 42:2325-2329.

34. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs cooperative study. Arthritis Rheum 1996; 39:2004-2012.

35. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondyloparthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618-627.

36. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39:2021-2027.

37. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000; 27:714-718.

38. Cuellar ML, Espinoza LR. Methotrexate use in psoriasis and psoriatic arthritis. Rheum Dis Clin North Am 1997; 23:797-809.

39. Sampiao-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000; 29:160-162.

40. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 2000; 19:114-117.

41. Marshall RW, Kirwan JR. Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001; 30:313-314.

42. Roychaudhry B, Bintley-Bagot S, Hunt J, Tunn EJ. Methotrexate in severe ankylosing spondylitis: a randomized placebo controlled, double- blind observer study [abstract]. Rheumatology 2001; 40(suppl 1):43.

43. Van den Bosch F, Kruithof E, Baeten D, de Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59:428-433.

44. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43:1346-1352.

45. Antoni C, Kavanaugh A, Kirkham B, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT) [abstract]. Arthritis Rheum 2002; 46(suppl):S381.

46. Feletar MH, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of recalcitrant psoriatic arthritis patients with infliximab- a 12-month observational study of 16 patients [abstract]. ACR/ARHP Annual Scientific Meeting, New Orleans, Louisiana, 2002.

47. Mease PJ, Goffe BS, Metz J, van der Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-390.

48. Mease PJ. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel): results of a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001; 44(suppl):S90.

49. Ory P, Sharp JT, Salonen D, et al. Etanercept (Enbrel) inhibits radiographic progression in patients with psoriatic arthritis [abstract]. Arthritis Rheum 2002; 46(suppl):S196.

50. Gladman DD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrotic factor alpha. N Engl J Med 2002; 346:1349-1356.

Cleveland Clinic Journal of Medicine
Volume 71, Number 3, March 2004

This paper discusses therapies that are experimental or are not approved by the U.S. Food and Drug Administration for use under discussion.